Health Care Equipment

Sinocare

Sinocare released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 1.239 B (forecast CNY 1.266 B), actual EPS CNY 0.18

Sinocare released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 1.206 B (forecast CNY 1.461 B), actual EPS CNY -0.217

Sinocare released FY2025 annual earnings on April 27 After-Market BJT, actual revenue CNY 4.659 B (forecast CNY 4.884 B), actual EPS CNY 0.1685 (forecast CNY 0.53)

Sinocare to Release FY2025 Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 4.884 B, EPS CNY 0.53

Sinocare FY2026 Q1 Earnings Release on April 28 During-Market (BJT), Forecast Revenue CNY 1.266 B

Insulet Agrees to Cease Sales Due to Patent Infringement

Sinocare released FY2025 Q3 earnings on October 23 After-Market (BJT), actual revenue CNY 1.19 B, actual EPS CNY 0.0554

Sinocare released FY2025 9 Months Earnings on October 23 After-Market (BJT), actual revenue CNY 3.453 B, actual EPS CNY 0.382

Sinocare to Release FY2025 Q3 Earnings on October 24 After-Market BJT

Sinocare released FY2025 Q2 earnings on August 27 During-Market (BJT), actual revenue CNY 1.222 B, actual EPS CNY 0.1964

Sinocare released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), actual revenue CNY 2.264 B, actual EPS CNY 0.3266

Sinocare FY2025 Semi-Annual Earnings Release on August 28, 2025 (BJT)

Suanovo Submits New Trademark Application and Discloses Data

Trinity Biotech's Continuous Glucose Monitoring System Receives EU Certification

Huaxin Securities Gives a Buy Rating to Snap Bio for the First Time

Trinity Biotech's CGM Product Enters FDA Substantive Review Supplement Stage

Triniti Bio applies for 27 new trademarks this year

Sinocare Receives Buy Rating, CGM Business Shines

Eastwu Securities Releases Research Report on Sunay Biotech

Sinocare released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 1.042 B, actual EPS CNY 0.1302

300298

In Shanghai on April 11, 2026, Sinocare unveiled its latest innovations at the 93rd China International Medical Equipment Fair (CMEF) with a focus on "Advancing Digital Healthcare for Global Well-being." The event showcased state-of-the-art technologies and comprehensive solutions aimed at transforming the healthcare landscape.

Unusual Whales

Sinocare Showcases Digital Innovation at the 93rd CMEF, Advancing Global Chronic Disease Management

Sinocare: Plans to repurchase shares worth RMB 150 million to 300 million, with the repurchase price not exceeding RMB 25 per share

Wallstreetcn

520880

159883

At the ATTD 2026, AI has emerged as a key topic in diabetes care. SIBIONICS introduced AI-driven features that transform everyday data into actionable insights, enhancing continuous glucose monitoring (CGM) beyond mere tracking. Innovations include multi-day time in range (TIR) overviews and intelligent logging for better glucose pattern recognition. Healthcare professionals emphasize the importance of personalized AI tools that convert complex data into clear recommendations, supporting patient engagement and clinical decision-making. The symposium featured experts discussing advancements in diabetes technology and the evolving role of AI in improving diabetes management.

prnewswire

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

iShares US Healthcare Providers

Bosera Hang Seng SCHK Innovative Drug Select ETF

Beta Bionics

VG Health

Health Care Select Sector SPDR

Tandem Diabetes

ChinaAMC CSI Biotechnology Theme ETF

iShares Biotechnology ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fidelity Disruptive Medicine ETF

iShares US Medical Devices

Novo Nordisk AS

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Global X HealthTech ETF

E Fund CSI 300 Health Care ETF

iShares Global Healthcare

China Merchants CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

YUYUE MEDICAL

Invesco Nasdaq Biotechnology ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Proshares Ultra Nasdaq Biotech

Direxion Daily Robotics AI & Auto Bull 2X

Direxion S&P Biotech Bull 3X

Dacheng CSI All Share Health Care Equipment and Services ETF

SPDR S&P Health

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

VanEck Biotech ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

COFOE

Global X Funds Global X Artificial Intelligence & Tech ETF

Defiance Daily Target 2X Long NVO ETF

Penghua SSE STAR Biology and Medicine ETF

SI-BONE

First Trust NYSE Arca Biotech Index Fd

Tianhong CNI BIOMEDICINE ETF

Invesco Biotechnology & Genome ETF

Direxion Healthcare Bull 3X

Ark Genomic Revolution ETF

Yinhua CSI Innovative Drugs Industry ETF

SPDR S&P Health Equip

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

00:57 ETATTD Spotlight: Von Blutzuckerwerten zu KI-basierten Erkenntnissen - eine neue Richtung für das Diabetes-Management

According to the Zhitong Finance APP, Sinocare announced that as of October 31, 2025, the company has repurchased a total of 6.8275 million shares through centralized bidding, accounting for 1.22% of the company's current total share capital, with a total transaction amount of 139 million yuan (excluding transaction fees)

Zhitong

Sinocare has repurchased 1.22% of its shares, costing 139 million yuan

According to the Zhitong Finance APP, Sinocare released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.453 billion yuan, a year-on-year increase of 8.52%. The net profit attributable to shareholders of the listed company was 211 million yuan, a year-on-year decrease of 17.36%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 180 million yuan, a year-on-year decrease of 22.13%. The basic earnings per share were 0.3827 yuan

Sinocare released its performance for the first three quarters, with a net profit attributable to the parent company of 211 million yuan, a decrease of 17.36%

Sinocare showcased its comprehensive diabetes management solutions at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna. The company organized an international symposium highlighting the clinical performance of its iCan CGM system, featuring expert presentations on its effectiveness in adult and pediatric populations. Sinocare also launched the iCan i6 CGM, emphasizing its user-friendly design and global accessibility. Additionally, the company introduced its "A+C" Diabetes Prevention and Control Ecosystem, integrating non-invasive detection with continuous glucose monitoring for improved patient care.

00:22 ET
			
			
			
				
					Sinocare presenta sus soluciones integrales para el manejo de la diabetes en EASD

Sinocare showcased its comprehensive diabetes management solutions at the successful 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna. The company hosted an international symposium highlighting the clinical performance of its iCan CGM system, with presentations from experts on its effectiveness and usability. Sinocare also introduced the next-generation iCan i6 CGM system, featuring enhanced user experience and global accessibility. Additionally, the company presented its new diabetes prevention ecosystem, integrating non-invasive screening with CGM for early risk detection and intervention.

09:33 ET
			
			
			
				
					Sinocare präsentiert seine umfassenden Lösungen für das Diabetesmanagement auf der EASD

The European Association for the Study of Diabetes (EASD 2025) recently concluded its 61st Annual Meeting in Vienna, Austria. Sinocare organized a significant industry symposium and an exclusive networking dinner during the event. The conference gathered a large number of attendees and participants from around the world, highlighting the importance of the global fight against diabetes. The event showcased the latest advancements in diabetes research and treatment, underscoring the significance of international collaboration in addressing this pervasive health issue.

Sinocare presents diabetes solutions at EASD in Vienna. 61st Annual Meeting discusses latest trends in diabetes management.

Sinocare showcased its diabetes management solutions at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna. The company hosted a symposium featuring international experts discussing the iCan CGM's clinical performance. The new iCan i6 CGM system was launched, offering enhanced features for users. Sinocare also introduced its "A+C" Diabetes Prevention and Control Ecosystem, integrating non-invasive screening with CGM for early risk detection. The event emphasized Sinocare's commitment to technological innovation in diabetes care and global collaboration.

02:07 ET
			
			
				Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD

According to the Zhitong Finance APP, Sinocare announced that as of September 24, 2025, the company has repurchased a total of 6.1275 million shares through centralized bidding, accounting for 1.09% of the company's current total share capital, with a total transaction amount of 126 million yuan (excluding transaction fees)

Sinocare has repurchased 1.09% of its shares, costing 126 million yuan

Sinocare(300298.SZ)